Unlike the efficient inhibition of IL-17A production by the low-dose (1 μM) verteporfin treatment, the production of IL-6, IL-10, TNF-α, and IFN-γ in T cells from patients with SLE or RA was modestly inhibited by the low-dose (1 μM) verteporfin treatment (Fig. 5B). Here, IL10 is linked to systemic lupus erythematosus.